Permanent Prostate Brachytherapy in Men with Clinically Localised Prostate Cancer

Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion

This study aimed to evaluate rectal dose reduction in prostate cancer patients who underwent a combination of volumetric modulated arc therapy (VMAT) and low‐dose‐rate (LDR) brachytherapy with insertion of hydrogel spacer (SpaceOAR). For this study, 35 patients receiving hydrogel spacer and 30 patients receiving no spacer were retrospectively enrolled. Patient was treated to doses of 45 Gy to the primary tumor site and nodal regions over 25 fractions using VMAT and 100 Gy to the prostate using prostate seed implant (PSI). In VMAT plans of patients with no spacer, mean doses of rectal wall were 43.6, 42.4, 40.1, and 28.8 Gy to the volume of 0.5, 1, 2, and 5 cm³, respectively. In patients with SpaceOAR, average rectal wall doses decreased to 39.0, 36.9, 33.5, and 23.9 Gy to the volume of 0.5, 1, 2, and 5 cm³, respectively (p < 0.01). In PSI plans, rectal wall doses were on average 78.5, 60.9, 41.8, and 14.8 Gy to the volume of 0.5, 1, 2, and 5 cm³, respectively, in patients without spacer. In contrast, the doses decreased to 34.5, 28.4, 20.6 (p < 0.01), and 8.5 Gy (p < 0.05) to rectal wall volume of 0.5, 1, 2, and 5 cm³, respectively, in patient with SpaceOAR. To demonstrate rectal sum dose sparing, dose‐biological effective dose (BED) calculation was accomplished in those patients who showed >60% overlap of rectal volumetric doses between VMAT and PSI. In patients with SpaceOAR, average BED_sum was decreased up to 34%, which was 90.1, 78.9, 65.9, and 40.8 Gy to rectal volume of 0.5, 1, 2, and 5 cm³, respectively, in comparison to 137.4, 116.7, 93.0, and 50.2 Gy to the volume of 0.5, 1, 2, and 5 cm³, respectively, in those with no spacer. Our result suggested a significant reduction of rectal doses in those patients who underwent a combination of VMAT and LDR with hydrogel spacer placement.

Transrectal ultrasound based prostate volume determination: is the frustum algorithm more accurate than planimetry?

PURPOSE

To compare reconstructed volumes calculated via planimetry and frustum algorithms in the context of stepped transrectal ultrasound (US) imaging, and to estimate the reconstruction error for prostate volumes.

METHODS

Prostate contours for 40 permanent implant patients were delineated on magnetic resonance (MR) and transrectal US images by a radiation oncologist. Simulated images of ellipsoid and truncated cone geometrical objects were constructed to determine volume calculation accuracy. Simulation results were used to deduce the algorithm-associated error made when calculating transrectal US prostate volumes.

RESULTS

For imaging without deliberate slice positioning, planimetry reconstruction was mostly accurate while the frustum algorithm underestimated the volume. The discrepancy was mostly due to the end slice reconstruction. For slice positioning that reflected US image acquisition, planimetry overestimated by half the superior slice volume on average while frustum underestimated by half the inferior slice volume. The estimated algorithm errors for prostate contours were 4% and -3%, respectively.

CONCLUSIONS

The planimetry and frustum algorithms offer different interpretations for reconstruction and yield systematic differences in calculated volumes. Both algorithms introduce bias into transrectal US prostate volume determinations that may have clinical implications, planimetry overestimating and frustum underestimating the volume.

Comparison of prostate volume, shape, and contouring variability determined from preimplant magnetic resonance and transrectal ultrasound images

PURPOSE

To compare preimplant prostate contours and contouring variability between magnetic resonance (MR) and transrectal ultrasound images.

METHODS AND MATERIALS

Twenty-three patients were imaged using ultrasound (US) and MR before permanent brachytherapy treatment. Images were anonymized, randomized, and duplicated, and the prostate was independently delineated by five radiation oncologists. Contours were compared in terms of volume, dimensions, posterior rectal indentation, and observer variability. The Jaccard index quantified spatial overlap between contours from duplicated images.

RESULTS

The mean US/MR volume ratio was 0.99±0.08 (p=0.5). The width, height, and length ratios for the prostate were 0.98±0.06 (p=0.09), 0.99±0.08 (p=0.4), and 1.05±0.14 (p=0.1). Rectal indentation was larger on US by 0.18mL (p=0.01) and correlated with prostate volume (p<0.01). MR and US interobserver variability in volume were similar at 3.5±1.7 and 3.3±1.9mL (p=0.6). Intraobserver variability was smaller on US at 1.4±1.1mL compared with MR at 2.4±2.2mL (p=0.01). Local intraobserver variability was lower on US at the midgland slice (p<0.01) but lower on MR at the base (p<0.01) and apex (p<0.01) slices.

CONCLUSIONS

US is comparable to MR for preimplant prostate delineation, with no significant difference in volume and dimensions. Rectal indentation because of the transrectal ultrasound probe was measurable, although the effects were small. Intraobserver variability was lower on US for the prostate volume but was lower on MR locally at the base and apex. However, the difference was not observed for the interobserver variability, which was similar between MR and US.

Intraoperative 3D reconstruction of prostate brachytherapy implants with automatic pose correction

The success of prostate brachytherapy critically depends on delivering adequate dose to the prostate gland, and the capability of intraoperatively localizing implanted seeds provides potential for dose evaluation and optimization during therapy. REDMAPS is a recently reported algorithm that carries out seed localization by detecting, matching and reconstructing seeds in only a few seconds from three acquired x-ray images (Lee et al 2011 IEEE Trans. Med. Imaging 29 38-51). In this paper, we present an automatic pose correction (APC) process that is combined with REDMAPS to allow for both more accurate seed reconstruction and the use of images with relatively large pose errors. APC uses a set of reconstructed seeds as a fiducial and corrects the image pose by minimizing the overall projection error. The seed matching and APC are iteratively computed until a stopping condition is met. Simulations and clinical studies show that APC significantly improves the reconstructions with an overall average matching rate of ⩾99.4%, reconstruction error of ⩽0.5 mm, and the matching solution optimality of ⩾99.8%.

REDMAPS: reduced-dimensionality matching for prostate brachytherapy seed reconstruction

The success of prostate brachytherapy critically depends on delivering adequate dose to the prostate gland. Intraoperative localization of the implanted seeds provides potential for dose evaluation and optimization during therapy. A reduced-dimensionality matching algorithm for prostate brachytherapy seed reconstruction (REDMAPS) that uses multiple X-ray fluoroscopy images obtained from different poses is proposed. The seed reconstruction problem is formulated as a combinatorial optimization problem, and REDMAPS finds a solution in a clinically acceptable amount of time using dimensionality reduction to create a smaller space of possible solutions. Dimensionality reduction is possible since the optimal solution has approximately zero cost when the poses of the acquired images are known to be within a small error. REDMAPS is also formulated to address the "hidden seed problem" in which seeds overlap on one or more observed images. REDMAPS uses a pruning algorithm to avoid unnecessary computation of cost metrics and the reduced problem is solved using linear programming. REDMAPS was first evaluated and its parameters tuned using simulations. It was then validated using five phantom and 21 patient datasets. REDMAPS was successful in reconstructing the seeds with an overall seed matching rate above 99% and a reconstruction error below 1 mm in less than 5 s.

Prostate cancer treatment patterns among racial/ethnic groups in Florida

BACKGROUND

Prostate cancer is the second leading cause of cancer death among men in the United States. Blacks have the highest incidence and mortality rates. Treatment differences have been observed between black and white men. Brachy monotherapy (BMT) has become popular for localized prostate cancer because of its convenience, being the least invasive, and resulting in better quality of life during and after treatment. No studies have specifically examined BMT in treating localized prostate cancer by race/ethnicity.

OBJECTIVES

We sought to (1) describe treatment patterns among men with localized prostate cancer, (2) identify factors affecting the use of BMT, and (3) examine if there was any difference in BMT use by race and ethnicity.

METHODS

Florida cancer incidence data of 1994-2003 were used to extract information on men diagnosed with localized prostate cancer along with their demographics, primary payer at diagnosis, tumor stage and treatments. Logistic regression was performed to assess the likelihood of receiving BMT.

RESULTS

The study found that surgery and radiation were the 2 major single treatments for localized prostate cancer. The percent of patients receiving BMT treatment increased from 1994 through 2003. Men with the following characteristics were more likely to receive BMT than their counterparts: Non-Hispanic white, older, married, Medicare beneficiaries and military personnel, with well-differentiated tumor, and receiving treatment in facilities with high practice volume and/or located in urban counties.

CONCLUSION

There were racial/ethnic differences in localized prostate cancer treatment. Possible reasons for the differences require further research.

Detection of brachytherapy seeds using 3-D transrectal ultrasound

Detection of brachytherapy seeds plays a key role in dosimetry for prostate brachytherapy. However, seed localization using B-mode transrectal ultrasound (TRUS) still remains a challenge for prostate brachytherapy, mainly due to the small size of brachytherapy seeds in the relatively low-quality B-mode TRUS images. In this paper, we propose a new solution for brachytherapy seed detection using 3-D ultrasound. A 3-D reflected power image is computed from ultrasound RF signals, instead of conventional B-mode images. Then, implanted seeds are segmented in 3-D local search spaces that are determined by a priori knowledge, e.g., needle entry points and seed placements. Needle insertion tracks are also detected locally by the Hough transform. Experimental results show that the proposed solution works well for seed localization in a prostate phantom implanted according to a realistic treatment plan with 136 seeds from 26 needles.

Permanent prostate brachytherapy: a century of technical evolution

PURPOSE

To summarise the practical aspects of the development of techniques of interstitial permanent prostate brachytherapy (PPB) implantation. Prostate brachytherapy dates back to Pasteau's publication in 1913 describing the insertion of a radium capsule into the prostatic urethra to treat carcinoma of the prostate. Various implantation methods were employed but with unsatisfactory results until the development of the transrectal ultrasound in the 1980s. The subsequent two-stage Seattle technique allowed for a planned homogenous distribution of radioactive sources throughout the gland resulting in biochemical control comparable to surgical and external beam radiotherapy series. With the advent of advanced computer software and improved imaging, the technique has developed accordingly to a single stage procedure with on-table dosimetric assessment. The principles of targeting dose to the prostate while avoiding surrounding organs at risk remain as relevant today as nearly a century ago. There is an array of techniques to consider for the novice PPB provider. Whether the evolution of PPB techniques will translate into improved biochemical control is yet to be seen.

Evaluation of an automated seed loader for seed calibration in prostate brachytherapy

Automated seed loaders for permanent prostate implants are now commercially available. Besides improved radiation safety, these systems offer seed assay capability and ease of needle loading, making preplanned as well as intra‐operative implant procedures more time‐efficient. The Isoloader (Mentor Corp., CA) uses individual I125 seeds (SL‐125 ProstaSeed) loaded in up to 199 chambers inside a shielded cartridge. The unit performs seed counting and calibration using a built‐in solid‐state detector. In order to evaluate the reproducibility and accuracy of the calibration process, two test cartridges were measured with the Isoloader itself and compared with a well‐type ionization chamber (HDR‐1000Plus, Standard Imaging).

The air kerma strength measurements for all seeds using the Isoloader had a standard deviation of about 2.7%. For the eight seeds assayed more intensively using both the Isoloader and well chamber, the standard deviations of the measurements for each seed were in the range of 0.8% to 2.8% and 0.6% to 1.3%, respectively. The variation in the Isoloader calibration is attributed to small detector solid angle and bead geometry within seed capsules (verified by radiographs). The reproducibility of the air kerma strength measured by the Isoloader was comparable to that from the well chamber and was clinically acceptable. Seed strength measured with the Isoloader was on average 1%~2% larger than that measured with the well chamber, indicating that the accuracy of the Isoloader was clinically acceptable.

PACS numbers: 87.53.Jw, 87.53.Xd, 87.56.Fc

Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma

BACKGROUND

The impact of the increased use of permanent prostate brachytherapy compared with other treatment modalities (such as radical prostatectomy and external-beam radiation therapy [EBRT]) for the treatment of clinically localized prostate carcinoma, and the previously reported regional, racial, and age-related variations in prostate carcinoma treatment, have not been well characterized to date. Therefore, the authors evaluated the impact of permanent prostate brachytherapy on the relative rates of the use of specific prostate carcinoma treatment modalities over time.

METHODS

Surveillance, Epidemiology, and End Results (SEER) cancer registry data from 1995 to 2000 were analyzed in a longitudinal, observational study utilizing bivariate and multivariate techniques.

RESULTS

Differential changes in the use of specific definitive treatment modalities were noted by region, age group, racial/ethnic group, and marital status. Increasing use of permanent prostate brachytherapy, with and without concomitant EBRT, was proportional to the decreasing use of radical prostatectomy alone and EBRT alone over time.

CONCLUSIONS

The current study revealed that permanent prostate brachytherapy appears to be replacing other treatment modalities in increasing numbers of clinically localized prostate carcinoma cases. Persistent regional, racial/ethnic, marital status, and age-related differences in the use of permanent prostate brachytherapy merit further investigation.

Computing intraoperative dosimetry for prostate brachytherapy using TRUS and fluoroscopy

RATIONALE AND OBJECTIVES

There is a need to provide real-time dosimetric feedback during prostate brachytherapy based on the location of the implanted seeds. The objective of our approach is to develop a system to accurately locate seeds with minimal impact on the current protocol for prostate brachytherapy and without additional imaging equipment.

MATERIALS AND METHODS

A new approach for intraoperatively computing dosimetry for prostate brachytherapy is presented. The approach uses transrectal ultrasound (TRUS) and fluoroscopic images. A fluoroscopic image of the TRUS probe is required to register the fluoroscopic and ultrasound images. The C-arm is not moved during the procedure and all images are acquired from the same C-arm angles. A needle path is interpolated for each needle based on the location of the needle tip in TRUS images and the known entry point of the needle. Throughout the procedure, fluoroscopic images are acquired to determine the coronal plane coordinates of the seeds and the remaining coordinate of each seed is computed from the needle path. For accurate results, intraoperative seed motion tracking is advised and a method to achieve such tracking is also presented.

RESULTS

Experimentally, the TRUS and fluoroscopic images are registered with a mean and maximum error of 1.3 mm and 5.8 mm, respectively. In a phantom, 12 seeds are located using our approach and compared with the known locations, with a mean error in the x, y, and z direction of 0.96 mm, 0.33, and 0.68 mm, respectively, and a corresponding maximum error of 1.85 mm, 0.56 mm, and 1.63 mm. Experimental results show motion tracking in the y-direction with submillimeter accuracy. The feasibility of our approach is tested on five cases of clinical data using a semiautomated version of our system and the resulting dosimetry is compared with that found using postoperative computed tomography images. The D90 and V100 metrics computed using our approach and the computed tomography images differ by a maximum of 16.6% and 1.7%, respectively.

CONCLUSIONS

TRUS can be combined with single pose fluoroscopic images to compute delivered dose intraoperatively for prostate brachytherapy. Phantom results demonstrate the accuracy of the method and preliminary clinical results show its potential.

The emerging role of high-dose-rate brachytherapy for prostate cancer

By placing radioactive sources directly into the cancer, brachytherapy allows delivery of a highly conformal radiation dose to the prostate. Permanent seed brachytherapy is most commonly used for low-risk cancer, whereas high-dose-rate (HDR) brachytherapy is combined with external-beam radiotherapy to treat higher risk disease. The high rate of dose delivery and the large fraction size may be a radiobiological advantage for tumours with high sensitivity to radiation fraction size. The ability to optimise dose delivery allows for exquisite shaping of dose around the prostate and sparing of normal tissues. HDR brachytherapy is most commonly delivered in two or more fractions of 810 Gy combined with 40-50 Gy external beam. Published studies are almost entirely limited to single-institution case series. Most of the patients treated have relatively unfavourable localised disease, with a reported disease-free survival of 68-93%, and a local control rate of over 90%. Treatment is well tolerated, with urethral stricture the most common late effect (risk around 8%). Early results using HDR monotherapy in low-risk disease seem promising. Patients most likely to benefit from a combined HDR/external-beam approach have bulky local disease (stage T2b-T3) or intermediate to high-grade cancers. Prospective multicentre studies of HDR brachytherapy have begun in this patient group in Canada and the USA, which hopefully will allow future comparisons with high-dose conformal external-beam techniques.